Elecsys FT4 Ii Assay, Elecsys FT4 Ii Calset
Radioimmunoassay, Free Thyroxine. 510(k) K131244, from Roche Diagnostics (Indianapolis, IN). Product code CEC, class 2.
As of Nov 18, 2026, K131244 is an FDA 510(k) held by Roche Diagnostics, substantially equivalent on Jan 27, 2014 after 271 days, with no recalls tied to it in FDA's recall database.
- Substantially equivalent: Jan 27, 2014
- Review time: 271 days
- Recalls: 0
- Cited as a predicate by: 2 devices
Indications for Use
As the 510(k) summary states them, read from FDA's summary PDFElecsys FT4 II Reagent: The Elecsys FT4 II Assay is for the in vitro quantitative determination of free Thyroxine in human serum and plasma. Measurements obtained by this device are used in the diagnosis and treatment of thyroid diseases. The electrochemiluminescence immunoassay “ECLIA” is intended for use on Elecsys and cobas e immunoassay analyzers.
Predicate Devices
The legally marketed devices this 510(k) summary says it is substantially equivalent to, read from FDA's summary PDF- Elecsys FT4 AssayK961489 · Boehringer Mannheim Corp. · Jun 11, 1996
Cited as a Predicate
2 later 510(k) summaries name this device as a predicate- Elecsys FT4 IVK220456 · Roche Diagnostics · Apr 7, 2023
- Elecsys FT4 IIIK181233 · Roche Diagnostics · Sep 18, 2018
Other CEC Clearances
The newest 510(k)s for the same product code; see every CEC device- Access Free T4K240273 · Beckman Coulter, Inc. · Mar 6, 2024
- Elecsys FT4 IVK220456 · Roche Diagnostics · Apr 7, 2023
Record
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional
- Received
- May 1, 2013
- Review panel
- Clinical Chemistry
- Regulation
- 21 CFR 862.1695
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files